MOCHIDA PHARMACEUTICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,205 JPY | +0.47% |
|
+1.26% | -1.99% |
| Apr. 25 | Hidehiro Imatsu named president of Goldman Sachs Japan | RE |
| Mar. 21 | Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. | CI |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 225,342 | 161,603 | 164,177 | 141,444 | 116,879 | 113,178 | - | - |
| Enterprise Value (EV) 1 | 166,311 | 100,313 | 100,691 | 79,530 | 56,370 | 50,211 | 49,036 | 46,601 |
| P/E ratio | 26.7 x | 35.5 x | 19.3 x | 13.5 x | 18.7 x | 25.7 x | 19.2 x | 17 x |
| Yield | 1.5% | 1.92% | 2.1% | 2.41% | 2.4% | 2.51% | 2.51% | 2.51% |
| Capitalization / Revenue | 2.06 x | 1.59 x | 1.59 x | 1.28 x | 1.13 x | 1.11 x | 1.07 x | 1.05 x |
| EV / Revenue | 1.52 x | 0.99 x | 0.98 x | 0.72 x | 0.55 x | 0.49 x | 0.46 x | 0.43 x |
| EV / EBITDA | 12.3 x | 8.69 x | 6.83 x | 4.66 x | 5.04 x | 6.05 x | 4.86 x | 4.24 x |
| EV / FCF | 14,762,172 x | - | - | - | 10,986,079 x | - | 13,376,003 x | 9,477,614 x |
| FCF Yield | 0% | - | - | - | 0% | - | 0% | 0% |
| Price to Book | 1.78 x | 1.34 x | 1.29 x | 1.09 x | 0.96 x | 0.88 x | 0.86 x | 0.84 x |
| Nbr of stocks (in thousands) | 39,673 | 38,754 | 38,270 | 37,870 | 34,994 | 35,479 | - | - |
| Reference price 2 | 5,680 | 4,170 | 4,290 | 3,735 | 3,340 | 3,190 | 3,190 | 3,190 |
| Announcement Date | 5/13/19 | 5/15/20 | 5/14/21 | 5/13/22 | 5/15/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 109,643 | 101,799 | 102,995 | 110,179 | 103,261 | 102,000 | 106,000 | 108,000 |
| EBITDA 1 | 13,507 | 11,538 | 14,745 | 17,081 | 11,179 | 8,300 | 10,100 | 11,000 |
| EBIT 1 | 10,590 | 8,807 | 12,003 | 14,392 | 8,507 | 5,500 | 7,500 | 8,500 |
| Operating Margin | 9.66% | 8.65% | 11.65% | 13.06% | 8.24% | 5.39% | 7.08% | 7.87% |
| Earnings before Tax (EBT) 1 | 11,642 | 6,273 | 11,900 | 14,591 | 9,044 | 5,600 | 7,600 | 8,600 |
| Net income 1 | 8,435 | 4,598 | 8,587 | 10,569 | 6,649 | 4,400 | 5,900 | 6,650 |
| Net margin | 7.69% | 4.52% | 8.34% | 9.59% | 6.44% | 4.31% | 5.57% | 6.16% |
| EPS 2 | 212.9 | 117.6 | 222.3 | 277.4 | 178.9 | 123.9 | 166.1 | 187.2 |
| Free Cash Flow | 11,266 | - | - | - | 5,131 | - | 3,666 | 4,917 |
| FCF margin | 10.28% | - | - | - | 4.97% | - | 3.46% | 4.55% |
| FCF Conversion (EBITDA) | 83.41% | - | - | - | 45.9% | - | 36.3% | 44.7% |
| FCF Conversion (Net income) | 133.56% | - | - | - | 77.17% | - | 62.14% | 73.94% |
| Dividend per Share 2 | 85.00 | 80.00 | 90.00 | 90.00 | 80.00 | 80.00 | 80.00 | 80.00 |
| Announcement Date | 5/13/19 | 5/15/20 | 5/14/21 | 5/13/22 | 5/15/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2020 S1 | 2021 S1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 51,512 | 51,623 | 26,647 | 54,009 | 30,805 | 25,365 | 27,692 | 25,508 | 53,200 | 28,194 | 21,867 | 24,747 | 24,729 | 49,476 | 28,742 | 23,782 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 6,200 | 7,229 | 2,948 | 6,131 | 6,914 | 1,347 | 4,265 | 1,014 | 5,279 | 5,077 | -1,849 | 2,515 | 1,437 | 3,952 | 1,839 | -291 |
| Operating Margin | 12.04% | 14% | 11.06% | 11.35% | 22.44% | 5.31% | 15.4% | 3.98% | 9.92% | 18.01% | -8.46% | 10.16% | 5.81% | 7.99% | 6.4% | -1.22% |
| Earnings before Tax (EBT) | 6,366 | 7,353 | - | 6,793 | 6,964 | - | 4,414 | - | 5,412 | 5,195 | - | 2,572 | - | 4,049 | 1,994 | - |
| Net income 1 | 4,592 | 5,411 | 2,263 | 4,916 | 5,264 | 389 | 3,155 | 768 | 3,923 | 4,158 | -1,432 | 1,688 | 1,150 | 2,838 | 1,606 | -44 |
| Net margin | 8.91% | 10.48% | 8.49% | 9.1% | 17.09% | 1.53% | 11.39% | 3.01% | 7.37% | 14.75% | -6.55% | 6.82% | 4.65% | 5.74% | 5.59% | -0.19% |
| EPS | 117.1 | 139.6 | - | 128.5 | 137.8 | - | 83.98 | - | 104.6 | 111.8 | - | 46.24 | - | 78.39 | 45.09 | - |
| Dividend per Share | 40.00 | 40.00 | - | 40.00 | - | - | - | - | 40.00 | - | - | - | - | 40.00 | - | - |
| Announcement Date | 11/5/19 | 11/2/20 | 11/5/21 | 11/5/21 | 2/4/22 | 5/13/22 | 8/1/22 | 11/4/22 | 11/4/22 | 2/6/23 | 5/15/23 | 8/4/23 | 11/2/23 | 11/2/23 | 2/5/24 | - |
1JPY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 59,031 | 61,290 | 63,486 | 61,914 | 60,509 | 62,967 | 64,142 | 66,577 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | 11,266 | - | - | - | 5,131 | - | 3,666 | 4,917 |
| ROE (net income / shareholders' equity) | 6.9% | 3.7% | 6.9% | 8.3% | 5.2% | 3.4% | 4.5% | 5% |
| ROA (Net income/ Total Assets) | 6.96% | 5.78% | 7.68% | 9.11% | 5.64% | 3.6% | 4.7% | 5.2% |
| Assets 1 | 121,212 | 79,490 | 111,813 | 116,028 | 117,819 | 122,222 | 125,532 | 127,885 |
| Book Value Per Share 2 | 3,189 | 3,114 | 3,318 | 3,424 | 3,470 | 3,612 | 3,698 | 3,806 |
| Cash Flow per Share | 286.0 | 187.0 | 293.0 | 348.0 | 251.0 | - | - | - |
| Capex 1 | 1,368 | 1,958 | 1,935 | 2,988 | 2,166 | 1,600 | 2,000 | 2,500 |
| Capex / Sales | 1.25% | 1.92% | 1.88% | 2.71% | 2.1% | 1.57% | 1.89% | 2.31% |
| Announcement Date | 5/13/19 | 5/15/20 | 5/14/21 | 5/13/22 | 5/15/23 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3,190
JPY
Average target price
3,200
JPY
Spread / Average Target
+0.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.99% | 719M | |
| +34.00% | 704B | |
| +27.17% | 577B | |
| -7.75% | 348B | |
| +18.53% | 327B | |
| +4.95% | 288B | |
| +14.66% | 234B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -4.89% | 147B |
- Stock Market
- Equities
- 4534 Stock
- Financials Mochida Pharmaceutical Co., Ltd.
